Allogene Therapeutics, Inc. - Common Stock (ALLO)

Historical Holders from Q1 2016 to Q3 2025

Symbol
ALLO on Nasdaq
CUSIP
019770106
Type / Class
Equity / Common Stock
Shares outstanding
226M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
162M
Holdings value
$201M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
167
Number of buys
89
Number of sells
-52
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Allogene Therapeutics, Inc. - Common Stock (ALLO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CITADEL ADVISORS LLC 6.1% $15.1M 13.3M Kenneth Griffin Jul 9, 2025
Belldegrun Arie 5.6% -1.67% $15.7M $77.4K 12.7M +0.5% Arie Belldegrun, M.D. Sep 30, 2025
BlackRock, Inc. 5.3% $17.6M 11.5M BlackRock, Inc. Mar 31, 2025
Chang David D 4.9% -2% $13.9M $122K 11.2M +0.88% David D. Chang, M.D., Ph.D. Sep 30, 2025
Lynx1 Capital Management LP 5.2% $16.7M 10.9M Lynx1 Capital Management LP Dec 31, 2024
FMR LLC 4.9% -58.2% $15.7M -$20.9M 10.2M -57% FMR LLC Feb 28, 2025

Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 162M $201M -$24.3M $1.24 167
2025 Q2 184M $208M -$15.4M $1.13 153
2025 Q1 197M $289M +$11.2M $1.46 167
2024 Q4 189M $402M -$12.9M $2.13 170
2024 Q3 164M $460M -$1.96M $2.80 152
2024 Q2 165M $385M +$75.2M $2.33 168
2024 Q1 131M $586M +$47.2M $4.47 154
2023 Q4 122M $390M -$22.1M $3.21 165
2023 Q3 129M $408M -$20.7M $3.17 149
2023 Q2 132M $658M +$77.6M $4.97 166
2023 Q1 117M $577M +$25.7M $4.94 174
2022 Q4 111M $698M +$14.7M $6.29 163
2022 Q3 106M $1.15B +$54.4M $10.80 180
2022 Q2 101M $1.15B +$111M $11.40 154
2022 Q1 91.7M $836M +$16.2M $9.11 172
2021 Q4 85.8M $1.28B -$105M $14.92 167
2021 Q3 86.1M $2.21B +$36.2M $25.70 164
2021 Q2 86.3M $2.25B -$84.5M $26.08 177
2021 Q1 86.5M $3.05B -$11.8M $35.30 169
2020 Q4 87.5M $2.21B +$86.5M $25.24 159
2020 Q3 83.1M $3.13B -$164M $37.71 158
2020 Q2 86.9M $3.72B +$671M $42.82 170
2020 Q1 73.7M $1.39B +$45.7M $19.44 114
2019 Q4 71.6M $1.86B +$73.7M $25.98 115
2019 Q3 68.7M $1.76B +$43.7M $27.26 96
2019 Q2 68.9M $1.69B +$152M $26.85 94
2019 Q1 65.4M $1.66B +$80.5M $28.91 87
2018 Q4 55M $1.47B +$1.47B $26.93 79
2016 Q2 0 $0 -$115K 0
2016 Q1 4.03K $115K $0 $28.51 1